Skip to main content
Pedram Razavi, MD, Oncology, New York, NY

PedramRazaviMDPhD

Oncology New York, NY

Breast Cancer

Medical Oncologist

Overview of Dr. Razavi

Dr. Pedram Razavi is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Tehran University of Medical Sciences School of Medicine and has been in practice 16 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 90 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2010 - 2013
  • University of Southern California
    University of Southern CaliforniaPhD, Cancer epidemiology , 2005 - 2009
  • University of Southern California
    University of Southern CaliforniaMPH, 2005 - 2007
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 2001

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2013 - Present
  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2013 - 2026
  • NJ State Medical License
    NJ State Medical License 2020 - 2025

Publications & Presentations

PubMed

Journal Articles

  • Accuracy of Magnetic Resonance Imaging–Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy  
    Elizabeth J Sutton, Lior Z Braunstein, Yolanda Bryce, Jill S Gluskin, Pedram Razavi, JAMA Network Open

Lectures

  • A deep dive into the cfDNA pool: Clonal hematopoiesis as a major source of somatic mutations 
    AACR Advances in Liquid Biopsies, Miami - 1/15/2020
  • The Genomic Landscape of Endocrine-Resistant Metastatic Breast Cancer 
    San Antonio Breast Cancer Symposium - 12/10/2019
  • Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • Susan G. Komen® Invests $21.7 Million in Research Focused on Improving Outcomes for Breast Cancer Patients
    Susan G. Komen® Invests $21.7 Million in Research Focused on Improving Outcomes for Breast Cancer PatientsJune 22nd, 2022
  • SABCS 2021: Understanding and Applying Liquid Biopsies
    SABCS 2021: Understanding and Applying Liquid BiopsiesMarch 1st, 2022
  • Grail Passes Early Test in Quest to Find Cancer in Blood
    Grail Passes Early Test in Quest to Find Cancer in BloodJune 6th, 2017
  • Join now to see all

Professional Memberships